ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1649

High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis

Marco Ulises Martinez-Martinez1, Maria Daniela De Avila2, Mario Perales3, Lourdes Baranda4, Susana Román Acosta5, Jaime Antonio Borjas García5 and Carlos Abud-Mendoza1, 1Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 2Regional Unit Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 3Regional Unit of Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 4Regional Unit of Rheumatology and Osteoposis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 5Nephrology Department, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: complement, immunology, Lupus nephritis, skin and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having systemic lupus erythematosus (SLE) if he or she has antinuclear or anti-dsDNA antibodies and biopsy-proven nephritis.2 Granular deposition of immunoglobulins at the dermoepidermal junction [lupus band (LB)] is distinctive of SLE, but its utility for SLE diagnosis is indefinite. The main objective was to evaluate concordance of immunoglobulin deposits between kidney and skin in patients with SLE. The secondary objective was to evaluate the accuracy of the LB as a diagnostic test for SLE in patients with lupus nephritis and controls with other non-SLE nephropathies.

Methods: All patients who required kidney biopsy in the last 10 months were invited to participate in the study. From all patients who signed informed consent, kidney and non-exposed-skin biopsies were taken at the same moment and were evaluated for immunoglobulins (IgG, IgM, IgA) and complement proteins (C1q and C3) deposits. A different evaluator assessed kidney and skin biopsies; nevertheless, to assess the technique’s reliability, we obtained a weighted kappa of 0.89 (CI: 0.78-0.99) when they evaluated the same set of 20 images. Intensity of fluorescence for each biopsy specimen was graded from 0 to 4 + (negative=0, and positive= 1-4+).

Results:

Results: We included 25 patients with lupus nephritis and 28 controls (other nephropathies). In the 25 patients with lupus nephritis, IgG was positive in 23 (92%) in kidney and 13 (52%) of skin biopsies; IgA in 20 (80%) of kidney and 4 (16%) of skin biopsies; IgM 23 (92%) of kidney and 9 (36%) of skin biopsies; C3 in 24 (96%) of kidney and 3 (12%) of skin; C1q in 24 (96%) and 11 (44%) of skin biopsies. The table 1 shows the high sensitivity and specificity of kidney immunoglobulin deposits for diagnosing SLE and highlights the good specificity of C1q, IgA, and IgM deposits in the skin.

Table 1. Accuracy of immunoglobulin deposits in skin or kidney for diagnosing SLE.

 

 

Sensitivity

Specificity

PPV

NPV

LR (+)

LR (-)

IgG skin

0.52 (0.20 – 0.46)

0.86 (0.67 – 0.96)

0.76 (0.50 – 0.93)

0.67 (0.49 – 0.81)

3.64 (1.36 – 9.72)

0.56 (0.36 – 0.87)

IgG kidney

0.92 (0-74 – 0.99)

0.79 (0.59 – 0.92)

0.79 (0.60 – 0.92)

0.92 (0.73 – 0.99)

4.29 (2.09 – 8.81)

0.10 (0.03 – 0.39)

IgA skin

0.47 (0.33 – 0.61)

1 (0.82 – 1.0)

1 (0.28 – 1.0)

0.57 (0.42 – 0.71)

∞

0.84 (0.71 – 1.0)

IgA kidney

0.80 (0.59 – 0.93)

0.79 (0.59 – 0.92)

0.77 (0.56 – 0.91)

0.81 (0.62 – 0.94)

3.73 (1.79 – 7.79)

0.25 (0.11 – 0.57)

IgM skin

0.36 (0.18 – 0.57)

0.93 (0.76 – 0.99)

0.82 (0.48 – 0.98)

0.62 (0.46 – 0.76)

5.04 (1.20 – 21.15)

0.69 (0.50 – 0.94)

IgM kidney

0.92 (0-74 – 0.99)

0.54 (0.34 – 0.72)

0.64 (0.46 – 0.79)

0.88 (0.64 – 0.99)

1.98 (1.31 – 3.0)

0.15 (0.04 – 0.59)

C3 skin

0.12 (0.03 – 0.31)

0.93 (0.76 – 0.99)

0.60 (0.15 – 0.95)

0.54 (0.39 – 0.69)

1.68 (0.31 – 9.25)

0.95 (0.79 – 1.13)

C3 kidney

0.96 (0.80 – 1.0)

0.68 (0.48 – 0.84)

0.73 (0.54 – 0.87)

0.95 (0.75 – 1.0)

2.99 (1.73 – 5.15)

0.06 (0.01 – 0.41)

C1q skin

0.44 (0.24 – 0.65)

1 (0.82 – 1.0)

1 (0.62 – 1.0)

0.67 (0.50 – 0.80)

∞

0.56 (0.40 – 0.79)

C1q kidney

0.96 (0.80 – 1.0)

0.79 (0.59 – 0.92)

0.80 (0.61 – 0.92)

0.96 (0.78 – 1.0)

4.48 (2.19 – 9.15)

0.05 (0.01 – 0.35)

 PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio, (+): positive, (-): negative.

Conclusion:

Deposits of immunoglobulins are more common in kidney than skin. High specificity of LB justifies its use as a diagnostic tool for SLE; the high specificity of LB suggests its utility for SLE diagnosis.

 References.

1.        Giannakakis K, Faraggiana T. Clin Rev Allergy Immunol 2011;40(3):170–80.

2.        Petri M, et al. Arthritis Rheum 2012;64(8):2677–86.


Disclosure:

M. U. Martinez-Martinez,
None;

M. D. De Avila,
None;

M. Perales,
None;

L. Baranda,
None;

S. Román Acosta,
None;

J. A. Borjas García,
None;

C. Abud-Mendoza,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-specificity-of-skin-immunoglobulin-deposits-for-diagnosing-sle-in-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology